Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Decreases By 53.5%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a significant drop in short interest in July. As of July 31st, there was short interest totaling 8,093 shares, a drop of 53.5% from the July 15th total of 17,399 shares. Based on an average daily volume of 14,409 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.6% of the company’s stock are short sold.

Global X Genomics & Biotechnology ETF Trading Down 1.2%

Shares of NASDAQ:GNOM traded down $0.70 during mid-day trading on Friday, hitting $58.36. 11,784 shares of the company traded hands, compared to its average volume of 15,683. The stock has a 50-day moving average price of $54.86 and a two-hundred day moving average price of $49.06. Global X Genomics & Biotechnology ETF has a 12-month low of $36.00 and a 12-month high of $59.99. The stock has a market cap of $85.21 million, a P/E ratio of -24.94 and a beta of 1.17.

Global X Genomics & Biotechnology ETF Announces Dividend

The company also recently disclosed a dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 29th were issued a dividend of $0.0579 per share. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s payout ratio is currently -27.35%.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several institutional investors have recently made changes to their positions in the company. C M Bidwell & Associates Ltd. purchased a new stake in Global X Genomics & Biotechnology ETF in the 2nd quarter valued at about $242,000. Bank of America Corp DE boosted its stake in shares of Global X Genomics & Biotechnology ETF by 67.8% in the 1st quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after buying an additional 48,394 shares during the last quarter. Wealth Management Partners LLC bought a new position in shares of Global X Genomics & Biotechnology ETF in the first quarter valued at approximately $244,000. Creative Financial Designs Inc. ADV grew its holdings in shares of Global X Genomics & Biotechnology ETF by 4.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after acquiring an additional 481 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in Global X Genomics & Biotechnology ETF by 30.9% during the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares during the period. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.